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Abstract
Cancer stem cells (CSCs) are a small subset of cancer cells capable of self-renewal and tumor maintenance. Eradicating
cancer stem cells, the root of tumor origin and recurrence, has emerged as one promising approach to improve lung cancer
survival. Cancer stem cells are reported to reside in the side population (SP) of cultured lung cancer cells. We report here the
coexistence of a distinct population of non-SP (NSP) cells that have equivalent self-renewal capacity compared to SP cells in
a lung tumor sphere assay. Compared with the corresponding cells in monolayer cultures, lung tumor spheres, formed from
human non-small cell lung carcinoma cell lines A549 or H1299, showed marked morphologic differences and increased
expression of the stem cell markers CD133 and OCT3/4. Lung tumor spheres also exhibited increased tumorigenic potential
as only 10,000 lung tumor sphere cells were required to produce xenografts tumors in nude mice, whereas the same
number of monolayer cells failed to induce tumors. We also demonstrate that lung tumor spheres showed decreased 26S
proteasome activity compared to monolayer. By using the ZsGreen–cODC (C-terminal sequence that directs degradation of
Ornithine Decarboxylase) reporter assay in NSCLC cell lines, only less than 1% monolayer cultures were ZsGreen positive
indicating low 26S proteasome, whereas lung tumor sphere showed increased numbers of ZsGreen-positive cells,
suggesting the enrichment of CSCs in sphere cultures.
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Introduction
Cancer stem cells (CSCs) are a small reservoir of self-sustaining
cells with the exclusive ability for self-renewal and tumor mainte-
nance [1]. Only a small subset of cancer cells within a tumor have the
characteristics of stem cells, and can thus initiate a tumor when
transplanted [3,4]. Putative CSCs in acute myelogenous leukemia
(AML) were first isolated in 1994 [5]. With the advances in
fluorescence activated cell sorting (FACS), and newly identified cell
surface markers suchas Sca-1, and CD133, CSCs can be isolated not
only from blood cancers, but also from solid tumors [1].
CSCs in human breast carcinoma have been identified as a rare
population of CD44
+/CD24
2/low/ESA
+ cells [6]. 100 of these
cells were able to form new tumors, whereas other tumor cells
failed to form tumors in SCID mice. Breast CSCs were also
indentified as CD44
+/CD24
2/Oct-4
+ by Ponti et al. in 2005 [7].
CSCs in colon cancer were found to be a less than 2.5% of the
population with positive CD133 expression [8], and recently
defined as CD44
+/CD166
+/ESA
+ [9]. Bronchioalveolar stem cells
(BASCs) were recently identified as the putative stem cell
population for lung adenocarcinoma, and could be isolated as
CD45
2/Pecam
2/Sca-1
+/CD34
+ cells by FACS [10]. CSCs in
small cell and non-small cell lung cancer were also reported as a
rare population of undifferentiated CD133
+ cells [11]. These were
able to self-renew as tumor spheres in serum-free medium, and
generate tumor xenografts phenotypically indistinguishable from
the original tumor, when injected in SCID mice.
An alternative approach for isolating stem cell populations is
through enrichment of side population (SP) cells [2]. SP cells are
identified by the capacity to efflux Hoechst dye, a process mediated
by the ATP-binding cassette transporter breast cancer resistance
protein (Bcrp-1) [12]. Since Goodell et al. first reported that the SP is
enriched in hematopoietic stem cells (HSCs)[13], SP cells have been
identified in a variety of normal and malignant tissues including the
lung [14]. Bcrp-1 deficient mice lacked the SP in bone marrow yet
had no substantial hematopoietic abnormalities [15]. Thus, the
precise functional relationship between the SP phenotype and stem
cell function remains unclear. Both SP and NSP fractions from the
DAOY medulloblastoma cell line were capable of reconstituting the
original parental population, and only slight clonogenic enrichment
was observed in the SP fraction [16].
Hematopoietic stem cells (HSCs) are reported to reside in the
SP fraction of adult mouse bone marrow (BM), however, a recent
report showed the coexistence of NSP HSCs that do not
significantly differ from SP HSCs in numbers, and self-renewal
capacity [17]. In addition, the CD34
2/lowc-Kit
+Sca-1
+ lineage
marker
2 cell population, which is highly enriched in mouse HSCs,
was almost equally divided into the SP and NSP cells. These were
in a quiescent state and showed uniform cell-cycle kinetics,
regardless of whether they were in the SP or NSP [17]. Further
characterization of the SP in cancer cells is therefore required to
fully assess the role these cells play in lung cancer.
Recent findings showed that chemotherapeutic drugs, such as
doxorubicin and cisplatin, could induce the propagation of CSCs
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13298in vitro [18]. These cells maintained their self-renewal capacity as
demonstrated by growth of tumor spheres in vitro, and had high
tumorigenic and metastatic potential following inoculation into
SCID mice. Chemotherapeutic drugs, such as cisplatin and
ifosfamide, are also known to depress the expression of
proteasomal subunits [19], and down-regulate ubiquitin-protea-
some-dependent proteolysis [20]. Reduced 26S proteasome
activity was found to be a unique feature of CICs (cancer
initiating cells) in glioma and breast cancer, that could be used to
track CSCs in vivo [21]. However, Benzyloxicarbonyl-Leu-Leu-
Nle-CHO (LLNle), a c-secretase inhibitor, was reported to
effectively kill human glioblastoma tumor–initiating cells (GBM
TIC) in vitro by inhibition of the 26S proteasome. Therefore,
further elucidation of the 26S proteasome activity is required in
order to fully determine its role in CSCs and anticancer therapy.
Ultimately, this may aid in the identification of novel targets for
future therapeutic intervention.
In the present study, we investigated whether lung CSCs solely
reside in the side population and whether lung tumor spheres with
self-renewal capacity from NSCLC cell lines could be a source for
enrichment of lung CSCs.
Methods
Cell Culture
Human NSCLC cell lines A549 and H1299 were purchased
from American Type Culture Collection (Manassas, VA), and
cultured in RPMI 1640 media with 10% fetal bovine serum (FBS)
(Gibco) and penicillin and streptomycin cocktail (Gibco). 293 FT
cells were purchased from Invitrogen (Carlsbad, CA), and cultured
in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) with
10% FBS and penicillin and streptomycin cocktail. All cells were
cultured in a humidified incubator at 37uCa t5 %C O 2.
Staining of Cells with Hoechst 33342
Methods for identification of SPs were adapted from previous
reports [22,23]. Briefly, cells were trpsinized and resuspended at
1610
6 cells/ml in DMEM with high glucose, 2% (v/v) FBS, and
10 mM N-(2-hydroxyethyl) piperazine-N’-(2-ethanesulfonic acid)
(HEPES)), incubated with 5 mg/ml Hoechst 33342 dye (with or
without Fumitremorgin C (MP Biomedicals, Eschwege, Germany)
for 90 min in a 37uC water bath, and tubes were gently inverted
every 20 min to discourage cell settling and clumping. Cells were
centrifuged at 3756g for 6 min at 4uC, and resuspended in an
appropriate volume of cold Hank’s balanced salt solution (HBSS)
with 2% (v/v) FBS. The cells remained at 4uC for the remainder of
the experiment. For dead cell discrimination, 2 mg/mL of
propidium iodide (PI) were added immediately prior to flow
cytometry. Cell samples were analyzed on a MoFlo (Beckman
Coulter) cell sorter, and emission was collected through a 610 nm
long pass dichroic mirror (DCLP) to a 620 nm long pass (LP) filter
for the Hoechst red collection and a 424/44 nm band pass (BP)
filter for the Hoechst blue collection. The side population ‘‘SP’’
was identified as a group of cells able to exclude the Hoechst dye, a
characteristic abolished with 10 mM Fumitremorgin C treatment
[22].
Sphere Formation Assay
Lung tumor spheres were isolated through culture at low density
in serum-free culture condition as previously described, which
allowed the selection of undifferentiated cancer stem and
progenitor cells, while serum-dependent differentiated tumor cells
and non-transformed accessory cells were negatively selected
[8,11,24]. A549 and H1299 lung cancer cells were plated at clonal
density in serum free DMEM–F12 medium supplemented with,
5 mM HEPES, 0.1% sodium bicarbonate, 0.4% BSA, glutamine
and antibiotics (Gibco-Invitrogen), and containing 20 ng/ml EGF
and 10 ng/ml bFGF. Untreated tissue culture flasks were used to
reduce cell adherence and support growth as undifferentiated
tumor spheres. Medium was replaced or supplemented with fresh
growth factors twice a week until cells started to grow and form
floating aggregates. Tumor spheres were collected with a 100 mm
cell strainer (BD, Bedford, MA), and expanded by enzymatic and
mechanical dissociation, followed by re-plating of both single cells
and residual small aggregates in complete fresh medium.
Flow Cytometry
For flow cytometry, tumor spheres or monolayer cultures were
mechanically dissociated to single cells, washed and incubated with
the appropriate dilution of control or specific antibody. Antibodies
used were PE conjugated anti-CD133/1 from Miltenyi Biotec
(Bergisch Gladbach, Germany), FITC conjugated anti-CD44
(eBioscience, San Diego, CA), and anti-OCT3/4 (Santa Cruz
Biotechology, CA). For PE conjugated anti-CD133/1, cells were
first blocked with blocking reagent for 5 min, then a 20 min
incubation with antibody. For OCT3/4 expression, cells were
fixed and permeabilized with FIX & PERMH reagents (Invitrogen)
following manufacture’s instruction, and incubated with mouse
monoclonal antibody against Oct3/4 (Santa Cruz Biotechnology)
for 20 min in dark, after washed with PBS, cells were then
incubated in the dark with a FITC conjugated secondary antibody
(Invitrogen). As negative control, cells were stained with the
appropriate isotope control. For FITC conjugated anti-CD44,
cells were incubated with antibodies for 20 min in dark. After
washed with PBS, cells were analyzed on a FACS Calibur flow
cytometer (Becton Dickinson).
Proteasome Function Assays
Chymotryptic, tryptic, and caspase proteasome activities were
measured as described previously [25] with a few minor
modifications. A549, H1299 and their primary lung tumor sphere
cells were washed with phosphate buffered saline (PBS) and
pelleted by centrifugation. Cell pellets were sonicated in
homogenization buffer (25 mM Tris [pH 7.5], 100 mM NaCl,
5 mM ATP, 0.2% (v/v) Nonidet P-40 and 20% glycerol, and cell
debris were removed by centrifugation at 4uC. Protein concen-
tration in the resulting crude cellular extracts was determined by
the Micro (bicinchoninic acid) protocol (Bio Rad, Rockford, IL)
with BSA (Sigma) as standard. To measure 26S proteasome
activity, 100 mg of protein from crude cellular extracts of each
sample was diluted with buffer I (50 mM Tris [pH 7.4], 2 mM
dithiothreitol, 5 mM MgCl2, 2 mM ATP) to a final volume of
1 mL (assayed in quadruplicate). The fluorogenic proteasome
substrates Suc-LLVY-AMC (chymotryptic substrate; Biomol
International, Plymouth Meeting, PA), Z-ARR-AMC (tryptic
substrate; Calbiochem), and Z-LLE-AMC (caspase-like substrate;
Biomol International) were dissolved in DMSO and added to a
final concentration of 80 mM. Proteolytic activities were contin-
uously monitored in 2 hr at 37uC by measuring the release of the
fluorescent group, 7-amido-4-methylcoumarin (AMC), at a
fluorescence plate reader (Spectramax M2, Molecular Devices,
Sunnyvale, CA) with excitation and emission wavelengths of 380
and 460 nm, respectively.
Alamar Blue Assay
Cell viability was measured by Alamar Blue[26]. A549 and
H1299 cells were seeded in 96-well plates (BD Falcon) at a density
of 2610
3 cells per well. For tumor sphere cultures, single cell was
Lung Cancer Stem Cells
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were exposed to different concentrations of cisplatin or doxoru-
bicin as indicated for 48 h. Alamar Blue (BioSource, Camarillo,
CA) was added directly to the culture media at 10% of the media
volume during the last 10 h of the 48 h exposure period.
Fluoresces with an excitation of 544 nm and emission detected
at 590 nm was measured using a microplate reader.
Generation of Stable Cell Lines Expressing ZsGreen-cODC
Fusion Proteins Using Retroviral Transduction
The retroviral expression vector pQCXIN-ZsGreen-cODC was
a kind gift from Dr. Frank Pajonk (Division of Molecular and
Cellular Oncology, Department of Radiation Oncology, David
Geffen School of Medicine at University of California, Los Angeles,
Los Angeles, CA), in which the carboxyl terminus of the murine
ornithine decarboxylase (cODC) degron, the sequence that directs
the starting place of degradation, was fused to ZsGreen reporter
[21]. pQCXIN-ZsGreenc-ODC was co-transfected with pVSV-G
into GP2-293 pantropicretroviralpackagingcells (Clontech)and the
retrovirus supernatant was used to infect A549 and H1299 cells.
48 hrafterinfection,cellswereselected with G418(Invitrogen).The
accumulation of ZsGreen-cODC protein was monitored by
fluorescence microscope and flow cytometry (FL-1channel).
Generation of Subcutaneous Lung Cancer Xenografts in
Nude mice
F o rm i c ex e n o g r a f t s ,b o t hm o n o l a y e ra n dt u m o rs p h e r ec e l l sw e r e
trypsinized and mechanically dissociated to obtain single cell
suspensions before subcutaneous injection. Six-week-old female nude
mice (Harlan Lab, Indianapolis, IN) were used. Tumor sphere
(1610
4) and monolayer (1610
4) cellswere s.c. injected into the left and
right flanks of the same mouse to evaluate tumorigenic activity. Mice
were monitored daily for the appearance of subcutaneous tumors.
Mice were sacrificed at day 60 and tumor tissue was collected. Tumor
volume was calculated by the formula 0.526length6width
2.H e m a -
toxylin and eosin staining followed by IHC analysis were performed to
Figure 1. SP and NSP cells form tumor spheres with equal capacity in human adenocarcinoma cell lines. A. Characteristic Hoechst
33342 dye staining profile demonstrating the existence of SP (polygon gated) and NSP (ellipse gated) cells in human A549 and H1299
adenocarcinoma cells. Percentage of SP cells is indicated. Cells were stained with 5 mg/ml Hoechst33342 (HO), and control cells were also co-stained
with 10 mM fumitremorgin C (FTC) to specify the SP cells. Cells were sorted using a Beckman MoFlo cytometer and data were annotated using FCS
Express. B. Phase-contrast photographs of lung tumor spheres obtained from SP and NSP cells. SP and NSP cells (1000 cell/ml) were plated onto ultra
low adherent flasks in serum free media supplemented with growth factors and cultivated as described in Material and Methods. C. Re-stain of SP
and NSP cells from A549 and H1299 with Hoechst 33342 dye. Percentage of SP cells is labeled.
doi:10.1371/journal.pone.0013298.g001
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against b-catenin by standard IHC protocol.
Statistical Analysis
Data are presented as means 6 SD. Differences were
determined by two tailed Student’s t test. A P value of ,.05 was
considered significant.
Results
SP and NSP cells form tumor sphere with the same
frequency in human adenocarcinoma cell lines
SP cells have been implicated as putative CSCs as they show
elevated tumorigenicity in nude/scid mice compared to NSP
cells[27]. To determine whether SP cells have greater self-renewal
capacity than NSP cells in culture, SP and NSP cells from two
human lung cancer cell lines were sorted based on the ability to
efflux Hoechst 33342 dye to generate a Hoechst blue-red profile.
A selective ABCG2 inhibitor, Fumitremorgin C (FTC), was co-
incubated with Hoechst 33342 to block the activity of the
transporter, and the SP gate was defined as the diminished region
in the presence of FTC. The human adenocarcinoma cell lines
A549 and H1299 contained 17.7% and 0.2% SP cells, respectively
(Fig. 1A). Culturing of SP and NSP cells in tumor sphere forming
media, which only allows for selection of undifferentiated clones or
cancer stem and progenitor cells [11], resulted in lung tumor
sphere formation from both subpopulations with no difference in
the rate of formation (Fig. 1B and data not shown). SP cells
typically give rise to SP and NSP cells by means of asymmetric cell
division, whereas NSP cells do not have this potential [28]. By re-
staining the sorted SP and NSP cells from A549 and H1299 cells
one week after, FACS analysis revealed that the SP cells gave rise
Figure 2. Lung tumor spheres exhibit cancer stem cell features. A. Lung tumor spheres showed increased CD133 expression. Expression of
CD44 and CD133 in monolayer and tumor sphere cells, as determined by two-color flow cytometry analysis. Isotype-matched monoclonal antibodies
and a preimmune second antiserum were used as negative controls. The percentage of single- and double-positive cells are indicated. B. Lung tumor
spheres showed increased OCT3/4 expression. An average fluorescence intensity of OCT3/4 in control (grey area), monolayer cells (dotted line) and
tumor spheres (solid line) is shown. Percentages of positive cells are indicated in the table.
doi:10.1371/journal.pone.0013298.g002
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cells also gave rise to similar proportion of SP cells (Fig. 1C).
Lung tumor spheres exhibit cancer stem cell features
Since cells capable of self-renewal reside in both side and non-side
populations, we investigated whether tumor sphere cells showed any
CSC features, such as the expression of stem cell markers, such as
CD44, CD133 and OCT3/4. First, to rule out the effect of CSC
media on the expression, monolayer cells grown in the CSC media
were checked, and no difference was found between cells grow in CSC
media and regular growth media (data not shown). Cells from
monolayer and sphere cultures from A549 and H1299 cells were then
harvested, and analyzed for CD44 and CD133. Over 90% of A549
and H1299 cells in monolayer cultures were CD44
+,w h e r e a so n l ya
very small portion of cells were CD133
+ (0.2% in A549 cells, and
0.55% in H1299 cells.). However, in lung tumor spheres, CD133
+
cells were greatly enriched to over 10% in A549, and 1.7% in H1299
(Fig. 2A). The transcription factor OCT3/4 is considered a central
regulator of human embryonic stem cell pluripotency and self-renewal
capacities. Its expression appears to be important in maintaining the
undifferentiated state of embryonal carcinoma, as well as in other
cancers [29,30]. OCT3/4
+cells in A549 and H1299 monolayers were
less than 4%, whereas the numbers were significantly up-regulated in
tumor spheres to 36% and 50%, separately.
Lung tumor spheres have high tumorigenic potential
To determine whether lung tumor spheres from A549 and
H1299 cells differ in their tumorigenic potential compared to cells
grown in a monolayer, we injected 10,000 cells subcutaneously
from each of these populations into the flanks of nude mice.
Tumor growth was observed in all mice inoculated with tumor
sphere cells derived from A549, whereas no tumor growth was
observed after inoculation with monolayer A549 cells (Table 1).
Tumor sphere cells from H1299 cells grew in 2 out of 3 nude mice,
whereas the same number of monolayer cells failed to give rise to
any tumor even with an extended 4 more weeks of observation
(Table 1 and data not shown). H&E staining revealed a highly
cellular mass with large nuclei and prominent nucleoli (Fig. 3).
Tumor sections from xenografted tumor spheres were stained
using an antibody against b-catenin, which is a key regulator of the
Wnt pathway which functions in controlling stem cell self-renewal.
The translocation of b-catenin to the nucleus leads to the
enhanced expression of b-catenin target genes that promote
tumor establishment, growth, and invasion [31]. We observed that
b-catenin was expressed mainly in the cytoplasm, whereas
expression in the nuclei was observed in tumor sphere induced
tumor sections (Fig. 3). Translocation of b-catenin to the nucleus
leads to the enhanced expression of b-catenin target genes that
promote tumor establishment, growth, and invasion [31].
Lung tumor spheres are more resistant to
chemotherapeutic agents
M o n o l a y e ra n dt u m o rs p h e r ec e l l sw e r ee x p o s e dt od i f f e r e n t
concentrations of chemotherapeutic drugs currently in use in the
Table 1. Lung tumor spheres have high tumorigenic
potential.
A549 H1299
monolayer
Tumor
Sphere monolayer
Tumor
Sphere
Tumor formation 0/3 3/3 0/3 2/3
Tumor size (mm
3) 438 1011
Tumorigenic potential of tumor sphere cells is greater than monolayer cancer
cells. Monolayer and tumor sphere cells from A549 were injected s.c. into
athymic nude mice at concentrations of 1610
4 cells/ml. Mice were sacrificed at
day 60, and tumor was surgically removed and measured, and the mean values
of the tumor size were shown in the table.
doi:10.1371/journal.pone.0013298.t001
Figure 3. Histopathologic examination of the engrafted tumors by H&E and b-Catenin staining. Surgically removed tumor was fixed in
buffered formalin and subsequently analyzed by immunohistochemistry (IHC) by standard protocol.
doi:10.1371/journal.pone.0013298.g003
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13298clinical setting, such as cisplatin and doxorubicin. Cell viability
was measured by Alamar Blue assay 2 days after subjecting
m o n o l a y e ra n dt u m o rs p h e r ec e l l sto cisplatin or doxorubicin. As
s h o w ni nF i g4 ,t h ev i a b i l i t yo fm o n o l a y e rc u l t u r e sd e c r e a s e d
significantly after both chemotherapeutic agents treatments
compared to that of tumor sphere cells. The relative viability
was around 20% for both A549 and H1299 monolayer cultures
when treated with 12.5 mM of doxorubicin, while over 50% of
Figure 4. Chemoresistence of monolayer and tumor sphere. A. cisplatin, B. doxorubicin resistance of monolayer culture and tumor spheres
were analyzed. Cells dissociated from lung tumor spheres or monolayers were plated out in 96-well plate at 2610
4 cells/ml, 24 h later, media
containing different concentrations of cisplatin or doxorubicin was added. After 48 h culturing, 10% Alamar Blue was added and read at 544/590 nm,
the percent viability was calculated relative to cells not exposed to any chemotherapeutic drugs. The results represent the means 6 SD.
doi:10.1371/journal.pone.0013298.g004
Figure 5. Decreased proteasome activities of the 26S proteasome in A549 and H1299 tumor spheres. A. caspase-like, B. chymotrypsin-
like, and C. trypsin-like activity of monolayer culture and tumor spheres from A549 and H1299 cells was measued over the indicated times. D. End
point analysis (120 min) of 26S proteasome activities in monolayer cultures and tumor spheres. Mean 6 SD is plotted and derived from three
independent experiments. Student’s paired, and two-tailed t-tests were performed, *p,0.05, **p,0.01, and ***p,0.001 (three replicates per
experiment).
doi:10.1371/journal.pone.0013298.g005
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survived. When treated with 25 mM of cisplatin, the relative
viability was 11.7% for A549 and 25.3% for H1299 monolayer
culture, whereas 65.4% of A549 tumor sphere and 79.3% of
H1299 tumor sphere cells survived this treatment, indicating
monolayer culture may be more sensitive to cisplatin and
doxorubicin compared to tumor spheres, as demonstrated by
t h el e s sp e r c e n t a g eo fv i a b l ec e l l sa f t e ri nv i t r oe x p o s u r et ot h e
drug.
Lung tumor spheres exhibit reduced proteasome activity
Down-regulation of ubiquitin-proteasome-dependent proteoly-
sis was observed in response to various chemotherapeutic agents,
such as cisplatin [19], ifosfamide [19] and Bortezomib [32].
Recent findings showed that chemotherapeutic drugs, such as
cisplatin, can also lead to propagation of CSCs [18]. To investigate
whether reduced proteasome activity is observed in lung CSCs, we
performed fluorogenic proteasome function assays using mono-
layer and sphere cultures from A549 and H1299 human NSCLC
Figure 6. Track CSCs in tumor sphere based on their proteasome activity. A. Frequency of ZsGreen cells in A549 and H1299 monolayer
cultures. B. Frequency of ZsGreen cells in A549 and H12199-derived tumor spheres with accumulation of ZsGreen-cODC, and thus low proteasome
activity is indicated. C. Number of spheres formed from the ZsGreen positive and the ZsGreen negative cells after sorting with flow cytometry into
96-well plates. ZsGree-positive and –negative cells were sorted into 96-well plate (100cells/well), after cultured in tumor sphere media for 2 weeks;
number of formed spheres was counted. Student’s paired, and two-tailed t-tests were performed, ***p,0.001 (three replicates per experiment).
doi:10.1371/journal.pone.0013298.g006
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proteolytic activities including chymotrypsin-, trypsin-, and
caspase-like activities. To monitor specific protease activities of
the 26S proteasome, three fluorogenic substrates: Suc-LLVY-
AMC for chymotrypsin-like, Z-ARR-AMC for trypsin-like, and Z-
LLE-AMC for caspase-like activity, were incubated with cell
lysates from either monolayer or lung tumor sphere cultures.
Caspase-like and chymotrypsin-like activities from monolayers
increased over 2 hours of incubation with substrates, but remained
unchanged in tumor sphere lysates. Chymotrypsin-like activities
were similarly increased in monolayer cultures and less so in lung
tumor spheres (Fig. 5A, B). Trypsin-like activity was not
significantly different in both groups (Fig. 5C). Chymotrypsin-like
activity, the predominant activity of the 26S proteasome, was
reduced to about 30% in the sphere cultures relative to monolayer
cultures. Caspase-like activity was reduced to about 20%, whereas
the trypsin-like activity was not significantly different (Fig. 5D).
This result indicates that lung tumor sphere cultures have lower
26S proteasome activity than monolayer cultures.
Lung tumor spheres are enriched with cells with low
proteasome activity
Proteasomal degradation of most proteins must first go
through the ubiquitination pathway before being degraded by
the proteasome. However, ornithine decarboxylase (ODC) is a
well-characterized cellular protein subject to ubiquitin-indepen-
dent proteasomal degradation, and once recognized by 26S
proteasome, it leads to immediate degradation of the proteins
that contain it [21]. Retrovirus expressing ZsGreen-cODC (i.e.
fusion of a fluorescent protein ZsGreen, and the C-terminus of
the murine ornithine decarboxylase (cODC) degron) permits
identification of cells with reduced 26S proteasome activity due
to ZsGreen fluorescence. This has previously been reported to
track CICs in glioma and breast cancer in vitro based on its
capability to label live cells with low 26S proteasome activity
[21]. To confirm that tumor sphere cells are enriched for lung
CSCs, we infected A549 and H1299 cells with the ZsGreen-
cODC expressing retrovirus. We observed that monolayer
cultures of A549 and H1299 exhibited low background
fluorescence in more than 98% of the cells, and only very few
cells (2%) displayed high levels ofZ s G r e e n( F i g .6 Aa n dd a t an o t
shown). Interestingly, lung tumor spheres derived from ZsGreen-
cODC infected A549 and H1299 cells were greatly enriched for
ZsGreen-positive cells, indicating low proteasome activity and
thus a highly enriched source for CSCs (Fig. 6B). To further
confirm that CSCs are enriched in the population with low
proteasome activity, ZsGreen-positive and –negative cells were
also sorted into 96-well plate, and the number of spheres formed
out of 100 sorted cells were counted, ZsGreen-positive cells from
both A549 and H1299 cell lines had a statistically significantly
higher sphere-forming capacity compared to the ZsGreen-
negative cells (Fig.6C).
Discussion
In the present study, we have shown that: 1) consistent with
previousevidence[11],CSC-likecellsdoexistinlungcancer;2)both
SP and NSP cells form tumor spheres with equal frequency
indicating the existence of self-renewal CSC-like cells in both
populations; 3) lung CSC-like cells can be propagated in serum-free
media; and 4) low 26S proteasome activity is associated with lung
CSC-like cells. The cancer stem cell hypothesis predicts that the SP
fraction should be able to regenerate both the SP and NSP fractions
whereas the NSP fraction should only be able to regenerate itself
[28]. Interestingly, the results presented here demonstrate that both
the SP and the NSP fractions have the capacity to completely
regenerate both fractions. The same finding has also been observed
in C6 glioma and DAOY medulloblastoma cell lines where both
fractions were capable of reconstituting the parental cellular
population [16,33]. In the present study, SP cells displayed tumor
sphere-likegrowth, the classical invitro assay of self-renewal potential,
thereby confirming previous findings that SP cells display stem-like
activity [34]. However, NSP cells were also able to form tumor
spheres at a frequency comparable to that of SP cells.
CD133 (human prominin-1), a five transmembrane domain
glycoprotein, was originally identified as a cell surface antigen
present on CD34
+ hematopoietic stem cells. Recently, CD133 was
shown as a putative surface marker of cancer stem cells in many
solid tumors, such as brain tumor [35], prostate cancer [36], colon
cancer [8], ovarian cancer [37] and lung cancer [11]. The
extremely low abundance of CD133
+ or Oct3/4
+ cells in tumors,
makes it difficult to isolate these populations. In our study we show
that enrichment of CD133
+/Oct 3/4
+ cells by in vitro serum-free
culture is possible.
It has long been known that not every tumor cell is a tumor-
initiating cell, and thus millions of tumor cells are often required to
transplant a new tumor from an existing one. In the present study,
xenograft tumor growth in nude mice occurred with injection of
10,000 tumor sphere cells, but not by injecting an equal number of
monolayer cells. These tumors had large nuclei with prominent
nucleoli and nuclear staining of b-catenin, indicating possible
activation of Wnt pathway. Nuclear accumulation of b-catenin
[38] has been shown to play a role in controlling stem cell self-
renewal [31,39].
Chemotherapeutic drugs, such as cisplatin and ifosfamide [19],
are known to kill the bulk of tumors by down-regulating ubiquitin-
proteasome-dependent proteolysis [20]. However, they also lead to
the propagation of CSCs [18]. Decreased 26S proteasome activity
was reported as a feature of CSCs in glioma and breast cancer
cells, and this feature may be used to identify, track, and target
CSCs in vitro and in vivo [21]. Here we present novel observations
that chymotrypsin-like and caspase-like activities of the 26S
proteasome were significantly lower in lung cancer cell tumor
spheres compared to monolayer cultures. This suggests a new
target for drug intervention.
Acknowledgments
We thank Dr. Frank Pajonk and Dr. Erina Vlashi at University of
California for pQCXIN-ZsGreen-cODC plasmid, and Haris G. Vikis, Dr.
Jay W. Tichelaar, and Dr. Michael A. James for critical review of the
manuscript.
Author Contributions
Conceived and designed the experiments: JP MY. Performed the
experiments: JP QZ. Analyzed the data: JP. Contributed reagents/
materials/analysis tools: JP QZ YW. Wrote the paper: JP.
References
1. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer
stem cells–perspectives on current status and future directions: AACR Workshop
on cancer stem cells. Cancer Res 66: 9339–9344.
2. Asakura A, Rudnicki MA (2002) Side population cells from diverse adult tissues
are capable of in vitro hematopoietic differentiation. Exp Hematol 30:
1339–1345.
Lung Cancer Stem Cells
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e132983. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:
730–737.
4. Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts.
Annu Rev Med 58: 267–284.
5. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell
initiating human acute myeloid leukaemia after transplantation into SCID mice.
Nature 367: 645–648.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003)
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad
Sci U S A 100: 3983–3988.
7. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation
and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor
cell properties. Cancer Res 65: 5506–5511.
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007)
Identification and expansion of human colon-cancer-initiating cells. Nature 445:
111–115.
9. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, et al. (2007) Phenotypic
characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A
104: 10158–10163.
10. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, et al. (2005)
Identification of bronchioalveolar stem cells in normal lung and lung cancer.
Cell 121: 823–835.
11. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and
expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ
15: 504–514.
12. Hosford GE, Olson DM (2003) Effects of hyperoxia on VEGF, its receptors, and
HIF-2alpha in the newborn rat lung. Am J Physiol Lung Cell Mol Physiol 285:
L161–168.
13. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, et al. (1997) Dye
efflux studies suggest that hematopoietic stem cells expressing low or
undetectable levels of CD34 antigen exist in multiple species. Nat Med 3:
1337–1345.
14. Gebb SA, Shannon JM (2000) Tissue interactions mediate early events in
pulmonary vasculogenesis. Dev Dyn 217: 159–169.
15. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, et al. (2002) Bcrp1 gene
expression is required for normal numbers of side population stem cells in mice,
and confers relative protection to mitoxantrone in hematopoietic cells in vivo.
Proc Natl Acad Sci U S A 99: 12339–12344.
16. Srivastava VK, Nalbantoglu J (2008) Flow cytometric characterization of the
DAOY medulloblastoma cell line for the cancer stem-like phenotype.
Cytometry A 73: 940–948.
17. Morita Y, Ema H, Yamazaki S, Nakauchi H (2006) Non-side-population
hematopoietic stem cells in mouse bone marrow. Blood 108: 2850–2856.
18. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drug-
selected human lung cancer stem cells: cytokine network, tumorigenic and
metastatic properties. PLoS One 3: e3077.
19. Tilignac T, Temparis S, Combaret L, Taillandier D, Pouch MN, et al. (2002)
Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent prote-
olysis. Cancer Res 62: 2771–2777.
20. Fekete MR, McBride WH, Pajonk F (2005) Anthracyclines, proteasome activity
and multi-drug-resistance. BMC Cancer 5: 114.
21. Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, et al. (2009) In vivo
imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101:
350–359.
22. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and
functional properties of murine hematopoietic stem cells that are replicating in
vivo. J Exp Med 183: 1797–1806.
23. Eaker SS, Hawley TS, Ramezani A, Hawley RG (2004) Detection and
enrichment of hematopoietic stem cells by side population phenotype. Methods
Mol Biol 263: 161–180.
24. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, et al. (2006)
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:
1238–1241.
25. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL (1998) A proteolytic
system that compensates for loss of proteasome function. Nature 392: 618–622.
26. White MJ, DiCaprio MJ, Greenberg DA (1996) Assessment of neuronal viability
with Alamar blue in cortical and granule cell cultures. J Neurosci Methods 70:
195–200.
27. Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer
cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67:
4827–4833.
28. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, et al. (2009)
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are
susceptible to a targeted oncolytic virus. PLoS One 4: e4235.
29. Kraft HJ, Mosselman S, Smits HA, Hohenstein P, Piek E, et al. (1996) Oct-4
regulates alternative platelet-derived growth factor alpha receptor gene
promoter in human embryonal carcinoma cells. J Biol Chem 271: 12873–12878.
30. Sell S (2004) Stem cell origin of cancer and differentiation therapy. Crit Rev
Oncol Hematol 51: 1–28.
31. Prasad A, Paruchuri V, Preet A, Latif F, Ganju RK (2008) Slit-2 induces a
tumor-suppressive effect by regulating beta-catenin in breast cancer cells. J Biol
Chem 283: 26624–26633.
32. Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval
for the treatment of multiple myeloma progressing on prior therapy. Oncologist
8: 508–513.
33. Platet N, Mayol JF, Berger F, Herodin F, Wion D (2007) Fluctuation of the SP/
non-SP phenotype in the C6 glioma cell line. FEBS Lett 581: 1435–1440.
34. Harris MA, Yang H, Low BE, Mukherjee J, Guha A, et al. (2008) Cancer stem
cells are enriched in the side population cells in a mouse model of glioma.
Cancer Res 68: 10051–10059.
35. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003)
Identification of a cancer stem cell in human brain tumors. Cancer Res 63:
5821–5828.
36. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective
identification of tumorigenic prostate cancer stem cells. Cancer Res 65:
10946–10951.
37. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, et al. (2008)
Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer
18: 506–514.
38. Semba S, Kusumi R, Moriya T, Sasano H (2000) Nuclear Accumulation of B-
Catenin in Human Endocrine Tumors: Association with Ki-67 (MIB-1)
Proliferative Activity. Endocr Pathol 11: 243–250.
39. Mucenski ML, Nation JM, Thitoff AR, Besnard V, Xu Y, et al. (2005) Beta-
catenin regulates differentiation of respiratory epithelial cells in vivo. Am J Physiol
Lung Cell Mol Physiol 289: L971–979.
Lung Cancer Stem Cells
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13298